Literature DB >> 11674603

A Versatile Enantioselective Strategy Toward L-C-Nucleosides: A Total Synthesis of L-Showdomycin.

Barry M. Trost1, Lara S. Kallander.   

Abstract

Strategies for the synthesis of nucleosides that can provide either L or D isomers become more important as a result of the increasing number of such compounds that are therapeutically useful. The lower toxicity and reduced susceptibility toward metabolism of the L isomers make them particularly interesting. A strategy toward the C-nucleoside analogues has been explored in the context of the synthesis of L-showdomycin. The route involves an asymmetric desymmetrization using palladium catalysis of cis-2,5-diacyloxy-2,5-dihydrofurans available in one step from furan, with carbon nucleophiles. Nucleophilic synthons for a maleimide unit and a methoxycarbonyl unit have been designed. Two sequential palladium-catalyzed reactions introduce both substituents with excellent chemo-, regio-, diastereo-, and enantioselectivity. The presence of a double bond in this doubly alkylated compound at C-3 and C-4 allows easy structural variation. The use of an ester as a hydroxymethyl precursor also introduces a diversity element as well as having importance in its own right. The successful completion of a synthesis of L-showdomycin validates this approach as a viable strategy to C-nucleosides.

Entities:  

Year:  1999        PMID: 11674603     DOI: 10.1021/jo990195x

Source DB:  PubMed          Journal:  J Org Chem        ISSN: 0022-3263            Impact factor:   4.354


  2 in total

1.  Profiling Protein S-Sulfination with Maleimide-Linked Probes.

Authors:  Yu-Hsuan Kuo; Aaron M Konopko; Nicholas B Borotto; Jaimeen D Majmudar; Sarah E Haynes; Brent R Martin
Journal:  Chembiochem       Date:  2017-09-01       Impact factor: 3.164

2.  Acetoxy Meldrum's acid: a versatile acyl anion equivalent in the Pd-catalyzed asymmetric allylic alkylation.

Authors:  Barry M Trost; Maksim Osipov; Philip S J Kaib; Mark T Sorum
Journal:  Org Lett       Date:  2011-05-26       Impact factor: 6.005

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.